ASRGL1 strongly inhibits the development of hepatocellular carcinoma by inhibiting the formation of the cyclin B/CDK1 complex, ultimately leading to the failure of transition from the G2 to M phase of the cell cycle [38]. Here, CDK1 is linked to hepatocellular carcinoma.